A new compound that taken as a pill could be used as a preventative or treatment for influenza infections has been developed by California researchers.
The compound, known as a neuraminidase inhibitor, blocks an enzyme necessary for replication of the flu virus and may decrease the length and severity of flu systems and prevent the disease in people exposed to it, the researchers said Tuesday.
Labeled GS4104, the compound was developed by Dr. Choung U. Kim and Dr. Norbert Bischofberger, researchers at Gilead Sciences Inc. of Foster City, Calif., and colleagues at the University of California Berkeley and The Australian National University in Canberra.
An article describing their laboratory research appears in today’s issue of the Journal of the American Chemical Society.
Gilead said it plans to conduct human trials this year with Swiss company Hoffmann-LaRoche.
“It’s a big leap to jump from animals to humans, but we have every indication it will work in the same way,” Bischofberger said.
Local journalism is essential.
Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.
Subscribe to the Coronavirus newsletter
Get the day’s latest Coronavirus news delivered to your inbox by subscribing to our newsletter.